Given the active role of IKKα in the canonical NF-κB response to doxorubicin, it will be important to further identify the contributions of p52 activation to the ability of sarcoma cells to evade the toxicity of standard chemotherapy. The gene discussed is NFKB1; the disease is sarcoma.